Orthocell US expansion supports record revenue - ICYMI

Orthocell US expansion supports record revenue - ICYMI Published: 21:00 17 Jul 2026 EDT Orthocell Ltd (ASX:OCC, OTC:ORHHF) earlier this week reported record quarterly and full-year revenue as accelerating adoption of its Remplir™ nerve repair device strengthened the company’s commercial growth outlook. Revenue reached A$3.8 million in the June quarter, up 20% from the March period and 36% from the corresponding quarter last year. FY2026 revenue increased 44% to a record A$13.2 million, supported by product sales in Australia and a growing number of international markets. CEO and managing director Paul Anderson said revenue growth had been driven by product sales across Australia, Thailand, Hong Kong, Singapore, Canada and the United States. He stressed that Orthocell had not yet received the full financial benefit of its US rollout, describing the result as “great numbers with a whole heap of upside”. The United States is emerging as a central potential catalyst for Orthocell. Anderson said the company had established an eight-person team covering sales, marketing, medical education and science. That infrastructure was supporting distributors and helping expand surgeon and hospital engagement. He said distributors were also beginning to approach Orthocell after learning about the product, its differentiation and its pricing. Anderson regarded this inbound interest as evidence that the company’s US commercial platform was taking shape. Access to the US Department of Defense and Veterans Affairs networks could provide another catalyst. Anderson said participation in those networks was important for reaching the f...